Gemcitabine for Advanced Endometrial Cancer
Carcinosarcoma
Uterine cancer
DOI:
10.1097/igc.0b013e31824a33a2
Publication Date:
2012-05-24T15:21:31Z
AUTHORS (7)
ABSTRACT
<h3>Background</h3> Gemcitabine is active in several gynecologic malignancies including ovarian cancer, cervical and uterine leiomyosarcoma. It has been used an off-label setting for the treatment of advanced endometrial despite lack published data showing efficacy. We performed a retrospective study to determine progression-free survival response rate cancer patients treated with gemcitabine at Memorial Sloan-Kettering Cancer Center. <h3>Methods</h3> Eligible had histologically confirmed (stage IV or recurrent) that was single-agent Center between 1999 2009. Response therapy determined by review computed tomography imaging Evaluation Criteria Solid Tumors 1.1 criteria. <h3>Results</h3> Forty-six were included analysis. Median age 66 years (range, 52–87 years). All previously chemotherapy. The median number prior lines chemotherapy 2 1–8). dose administered 800 mg/m<sup>2</sup> infused on days 1 8 21-day cycle. Predominant histology endometrioid (48%, n = 22) followed serous (35%, 16), clear cell (15%, 7), undifferentiated (2%, 1). Overall 10.9% (95% confidence interval, 1.9%–19.9%); 5 (11%) achieved partial response. Thirteen (28%) displayed stable disease lasting least 3 months. Of note, (71%) 7 (n 5). 3.0 months 2.1–3.3 months). Nonhematologic grades 4 toxicities rare. Ten (22%) granulocyte colony-stimulating factor during treatment. Grade thrombocytopenia seen (9%). There no cases grade thrombocytopenia. <h3>Conclusions</h3> In mixed population well tolerated showed modest activity. Patients appeared have greater likelihood benefit.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (30)
CITATIONS (11)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....